Empiric Guideline-recommended Weight-based Vancomycin Dosing and Nephrotoxicity Rates in Patients with Methicillin-resistant Staphylococcus Aureus Bacteremia: a Retrospective Cohort Study

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2013 Feb 14

PMID 23402420

Citations 22

Authors

Ronald G Hall 2nd

Kathleen A Hazlewood

Sara D Brouse

Christopher A Giuliano

Krystal K Haase

Chistopher R Frei

Nicolas A Forcade

Todd Bell

Roger J Bedimo

Carlos A Alvarez

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have established a correlation between vancomycin troughs and nephrotoxicity. However, data are currently lacking regarding the effect of guideline-recommended weight-based dosing on nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteremia (MRSAB).

Methods: Adults who were at least 18 years of age with methicillin-resistant Staphylococcus aureus bacteremia and received of empiric vancomycin therapy for at least 48 hours (01/07/2002 and 30/06/2008) were included in this multicenter, retrospective cohort study. The association between guideline-recommended, weight-based vancomycin dosing (at least 15 mg/kg/dose) and nephrotoxicity (increase in serum creatinine (SCr) by more than 0.5 mg/dl or at least a 50% increase from baseline on at least two consecutive laboratory tests) was evaluated. Potential independent associations were evaluated using a multivariable general linear mixed-effect model.

Results: Overall, 23% of patients developed nephrotoxicity. Thirty-four percent of the 337 patients who met study criteria received weight-based dosing. The cohort was composed of 69% males with a median age of 55 years. The most common sources of MRSAB included skin/soft tissue (32%), catheter-related bloodstream bacteremia (20%), pulmonary (18%). Eighty-six percent of patients received twice daily dosing. Similar rates of nephrotoxicity were observed regardless of the receipt of guideline-recommended dosing (22% vs. 24%, OR 0.91 [95% CI 0.53-1.56]). This finding was confirmed in the multivariable analysis (OR 1.52 [95% CI 0.75-3.08]). Independent predictors of nephrotoxicity were (OR, 95% CI) vancomycin duration of greater than 15 days (3.36, 1.79-6.34), weight over 100 kg (2.74, 1.27-5.91), Pitt bacteremia score of 4 or greater (2.73, 1.29-5.79), vancomycin trough higher than 20 mcg/ml (2.36, 1.07-5.20), and age over 52 years (2.10, 1.08-4.08).

Conclusions: Over one out of five patients in this study developed nephrotoxicity while receiving vancomycin for MRSAB. The receipt of guideline-recommended, weight-based vancomycin was not an independent risk factor for the development of nephrotoxicity.

Citing Articles

Vancomycin-associated acute kidney injury in underweight patients: a propensity score matching analysis.

Okuwaki T, Kobayashi M, Kikuchi R, Tomoda Y, Ogawa M, Kasugai K Int Urol Nephrol. 2024; 57(4):1329-1336.

PMID: 39652231 DOI: 10.1007/s11255-024-04306-z.

Managing Dosage Adjustments in Pseudo-Hypocreatinemia: Insights from Vancomycin-Induced Nephrotoxicity in a Sarcopenic Patient.

Taniguchi S, Takata T, Mae Y, Fujino Y, Kageyama K, Hanada H Yonago Acta Med. 2024; 67(4):358-362.

PMID: 39583762 PMC: 11584231. DOI: 10.33160/yam.2024.11.005.

Retrospective Study of Factors Affecting the Accuracy of Predicting Vancomycin Concentrations in Patients Aged 75 Years and Above.

Takigawa M, Tanaka H, Kinoshita M, Ishii T, Masuda M Medicina (Kaunas). 2024; 60(8).

PMID: 39202554 PMC: 11356605. DOI: 10.3390/medicina60081273.

Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients.

Gorham J, Taccone F, Hites M Antibiotics (Basel). 2023; 12(7).

PMID: 37508195 PMC: 10376599. DOI: 10.3390/antibiotics12071099.

The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration's Adverse Event Reporting System (FAERS) Database.

Clifford K, Selby A, Reveles K, Teng C, Hall 2nd R, McCarrell J Antibiotics (Basel). 2022; 11(10).

PMID: 36290024 PMC: 9598234. DOI: 10.3390/antibiotics11101367.

References

Chow J, Yu V . Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999; 11(1):7-12. DOI: 10.1016/s0924-8579(98)00060-0. View

Wang G, Hindler J, Ward K, Bruckner D . Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006; 44(11):3883-6. PMC: 1698298. DOI: 10.1128/JCM.01388-06. View

Ellis-Grosse E, Babinchak T, Dartois N, Rose G, Loh E . The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005; 41 Suppl 5:S341-53. DOI: 10.1086/431675. View

Wilcox M, Tack K, Bouza E, Herr D, Ruf B, Ijzerman M . Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2008; 48(2):203-12. DOI: 10.1086/595686. View

Arbeit R, Maki D, Tally F, Campanaro E, Eisenstein B . The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004; 38(12):1673-81. DOI: 10.1086/420818. View

Rhee J, Kwon K, Ki H, Shin S, Jung D, Chung D . Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2008; 31(2):146-50. DOI: 10.1097/SHK.0b013e318182f98f. View

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

Lodise T, Lomaestro B, Graves J, Drusano G . Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52(4):1330-6. PMC: 2292536. DOI: 10.1128/AAC.01602-07. View

Kullar R, Davis S, Levine D, Rybak M . Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011; 52(8):975-81. DOI: 10.1093/cid/cir124. View

10.

Hall 2nd R, Giuliano C, Haase K, Hazlewood K, Frei C, Forcade N . Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis. 2012; 12:104. PMC: 3532187. DOI: 10.1186/1471-2334-12-104. View

11.

Rybak M, Lomaestro B, Rotschafer J, Moellering Jr R, Craig W, Billeter M . Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2008; 66(1):82-98. DOI: 10.2146/ajhp080434. View

12.

Jeffres M, Isakow W, Doherty J, Micek S, Kollef M . A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007; 29(6):1107-15. DOI: 10.1016/j.clinthera.2007.06.014. View

13.

Sakoulas G, Moise-Broder P, Schentag J, Forrest A, Moellering Jr R, Eliopoulos G . Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42(6):2398-402. PMC: 427878. DOI: 10.1128/JCM.42.6.2398-2402.2004. View

14.

Hidayat L, Hsu D, Quist R, Shriner K, Wong-Beringer A . High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166(19):2138-44. DOI: 10.1001/archinte.166.19.2138. View

15.

Tenover F, Moellering Jr R . The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007; 44(9):1208-15. DOI: 10.1086/513203. View

16.

Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C . Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49(6):2260-6. PMC: 1140485. DOI: 10.1128/AAC.49.6.2260-2266.2005. View

17.

Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley K . Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010; 123(12):1143-9. DOI: 10.1016/j.amjmed.2010.07.025. View

18.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

19.

Lodise T, Patel N, Lomaestro B, Rodvold K, Drusano G . Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49(4):507-14. DOI: 10.1086/600884. View

20.

Downs N, Neihart R, Dolezal J, Hodges G . Mild nephrotoxicity associated with vancomycin use. Arch Intern Med. 1989; 149(8):1777-81. View